Results 21 to 30 of about 350,217 (297)

Cyclic Stretching of Fibrotic Microtissue Array for Evaluation of Anti-Fibrosis Drugs. [PDF]

open access: yesCell Mol Bioeng, 2019
Progression of pulmonary fibrosis, characterized by the deterioration of lung tissue's mechanical properties, is affected by respiratory motion-induced dynamic loading. Since the development of anti-fibrosis drugs faces major hurdles in animal tests and human clinical trials, preclinical models that can recapitulate fibrosis progression under ...
Asmani M   +6 more
europepmc   +4 more sources

The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo

open access: yesBiomedicines, 2021
Cold Atmospheric Plasma (CAP) has shown promising results in the treatment of various skin diseases. The therapeutic effect of CAP on localized scleroderma (LS), however, has not yet been evaluated.
Stephanie Arndt   +4 more
doaj   +1 more source

Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model [PDF]

open access: yesInternational Journal of Ophthalmology, 2022
AIM: To confirm whether exosome-mediated delivery of aptamer S58 (Exo-S58) has a better antifibrotic effect than naked S58 in human conjunctival fibroblasts (HConFs) and a rat glaucoma filtration surgery (GFS) model.
Qian-Yi Lin   +9 more
doaj   +1 more source

Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects [PDF]

open access: yes, 2015
Chronic liver dysfunction or injury is a serious health problem worldwide. Chronic liver disease involves a wide range of liver pathologies that include fatty liver, hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
Feng, Y   +5 more
core   +5 more sources

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis

open access: yesFrontiers in Pharmacology, 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years.
Xudan Yang   +3 more
doaj   +1 more source

Ranunculus ternatus Thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2

open access: yesPharmaceutical Biology, 2022
Context Ranunculus ternatus Thunb (Ranunculaceae), (RTT) is used clinically for the treatment of tuberculosis or as tumour adjuvant therapy, but its potential effect on diabetic nephropathy (DN) has not been studied.
Weiwei Xu   +11 more
doaj   +1 more source

State of the ART: Drug Screening Reveals Artesunate as a Promising Anti-Fibrosis Therapy. [PDF]

open access: yesJ Respir Biol Transl Med
Fibrosis is a progressive pathological process that severely impairs normal organ function. Current treatments for fibrosis are extremely limited, with no curative approaches available. In a recent article published in Cell, Zhang and colleagues employed drug screening using ACTA2 reporter iPSC-derived cardiac fibroblasts and identified artesunate as a
Qiao Y, Liang J, Jiang D.
europepmc   +3 more sources

Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model. [PDF]

open access: yesTissue Eng Regen Med, 2020
Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited.Bone marrow-derived MSCs (BM-MSCs) were ...
Wang X   +8 more
europepmc   +4 more sources

Autophagy Inhibitor Chloroquine Downmodulates Hepatic Stellate Cell Activation and Liver Damage in Bile-Duct-Ligated Mice

open access: yesCells, 2023
Hepatic stellate cell (HSC) activation via the autophagy pathway is a critical factor in liver fibrogenesis. This study tests the hypothesis that chloroquine (CQ) treatment can prevent autophagy and HSC activation in vitro and in vivo in bile-duct ...
Trinh Van Le   +7 more
doaj   +1 more source

Anti-Ro52 Antibody as a Protective Factor for Pulmonary Fibrosis in Primary Sjögren's Syndrome [PDF]

open access: yesIranian Journal of Immunology, 2022
Background: Pulmonary fibrosis is common in primary Sjögren's syndrome (pSS)-related interstitial lung disease (ILD). However, research is lacking on the diagnostic immunological examination of pSS-related pulmonary fibrosis.
Defu Li   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy